title: Heparin therapy in pediatric patients: a prospective cohort study.
abstract: Current guidelines for heparin therapy in pediatric patients have been extrapolated from trials in adult patients without rigorous evaluation of efficacy and safety. We prospectively monitored consecutive pediatric patients receiving systemic doses of heparin over 10 mo at one institution using a predetermined nomogram to monitor maintenance therapy. Sixty-five consecutive children; 38 males and 27 females, received systemic doses of heparin. Thirty children had deep venous thrombosis and/or pulmonary embolism; 11 had arterial thrombi, most frequently after diagnostic angiography; and the remaining 24 received heparin prophylactically, for congenital heart disease. Twenty-nine (45%) of the 65 patients were less than 1 y of age and 22 (34%) were 10 y or older. Congenital heart disease was the predominant diagnosis under 1 y and deep venous thrombosis in older children. After a bolus dose of 50 U/kg, 39% of children (n = 30) achieved a minimal level activated partial thromboplastin time (APTT). Sixty-eight percent of children achieved a minimal level APTT by 24 h and 81% by 48 h. For all 65 children, APTT values were within the therapeutic range 43% of the time. APTT values outside the therapeutic range were twice as likely to be low as high. The average amount of heparin required to maintain therapeutic APTT values for children was 22 U/kg/h: 28 U/kg/h for infants < 1 y and 20 U/kg/h for the rest. Bleeding was rare (2%) and mild. Documented recurrent thrombotic disease was more common (7%) with associated morbidity.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pediatrics, McMaster University, Hamilton, Ontario.
authors.forename: M
authors.initials: M
authors.lastname: Andrew
authors.forename: V
authors.initials: V
authors.lastname: Marzinotto
authors.forename: P
authors.initials: P
authors.lastname: Massicotte
authors.forename: V
authors.initials: V
authors.lastname: Blanchette
authors.forename: J
authors.initials: J
authors.lastname: Ginsberg
authors.forename: P
authors.initials: P
authors.lastname: Brill-Edwards
authors.forename: P
authors.initials: P
authors.lastname: Burrows
authors.forename: L
authors.initials: L
authors.lastname: Benson
authors.forename: W
authors.initials: W
authors.lastname: Williams
authors.forename: M
authors.initials: M
authors.lastname: David
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002985:Clinical Protocols; D015331:Cohort Studies; D005260:Female; D006330:Heart Defects, Congenital / Q000097:blood / Q000188:drug therapy; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D008297:Male; D010314:Partial Thromboplastin Time; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000097:blood / Q000188:drug therapy; D013924:Thrombophlebitis / Q000097:blood / Q000188:drug therapy; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy
chemical_list: D006493:Heparin